JP2015524484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524484A5 JP2015524484A5 JP2015526726A JP2015526726A JP2015524484A5 JP 2015524484 A5 JP2015524484 A5 JP 2015524484A5 JP 2015526726 A JP2015526726 A JP 2015526726A JP 2015526726 A JP2015526726 A JP 2015526726A JP 2015524484 A5 JP2015524484 A5 JP 2015524484A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cognitive
- memory
- function
- enhancing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015654 memory Effects 0.000 claims description 19
- 230000003920 cognitive function Effects 0.000 claims description 18
- 230000002708 enhancing effect Effects 0.000 claims description 17
- 230000004633 cognitive health Effects 0.000 claims description 16
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 7
- 230000007787 long-term memory Effects 0.000 claims description 7
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 7
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 6
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 6
- 230000006403 short-term memory Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010003062 Apraxia Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 241000207923 Lamiaceae Species 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000027288 circadian rhythm Effects 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 206010013932 dyslexia Diseases 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000019771 cognition Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 230000036626 alertness Effects 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 22
- 208000024891 symptom Diseases 0.000 claims 7
- 230000002829 reductive effect Effects 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 230000002265 prevention Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681414P | 2012-08-09 | 2012-08-09 | |
| US61/681,414 | 2012-08-09 | ||
| PCT/US2013/054274 WO2014026081A1 (en) | 2012-08-09 | 2013-08-09 | Plant extracts for improving cognitive health and function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001953A Division JP2021066735A (ja) | 2012-08-09 | 2021-01-08 | 認知の健康および機能を向上させるための植物抽出物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524484A JP2015524484A (ja) | 2015-08-24 |
| JP2015524484A5 true JP2015524484A5 (enExample) | 2016-09-29 |
Family
ID=50066333
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526726A Pending JP2015524484A (ja) | 2012-08-09 | 2013-08-09 | 認知の健康および機能を向上させるための植物抽出物 |
| JP2021001953A Pending JP2021066735A (ja) | 2012-08-09 | 2021-01-08 | 認知の健康および機能を向上させるための植物抽出物 |
| JP2022196766A Pending JP2023027232A (ja) | 2012-08-09 | 2022-12-09 | 認知の健康および機能を向上させるための植物抽出物 |
| JP2024208100A Pending JP2025029029A (ja) | 2012-08-09 | 2024-11-29 | 認知の健康および機能を向上させるための植物抽出物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001953A Pending JP2021066735A (ja) | 2012-08-09 | 2021-01-08 | 認知の健康および機能を向上させるための植物抽出物 |
| JP2022196766A Pending JP2023027232A (ja) | 2012-08-09 | 2022-12-09 | 認知の健康および機能を向上させるための植物抽出物 |
| JP2024208100A Pending JP2025029029A (ja) | 2012-08-09 | 2024-11-29 | 認知の健康および機能を向上させるための植物抽出物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140044813A1 (enExample) |
| EP (1) | EP2882443B1 (enExample) |
| JP (4) | JP2015524484A (enExample) |
| KR (1) | KR101947352B1 (enExample) |
| CN (2) | CN111358832A (enExample) |
| AU (1) | AU2013299491B2 (enExample) |
| BR (1) | BR112015002739A2 (enExample) |
| CA (1) | CA2880708C (enExample) |
| ES (1) | ES2715005T3 (enExample) |
| PL (1) | PL2882443T3 (enExample) |
| WO (1) | WO2014026081A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507125A (ja) * | 2014-01-30 | 2017-03-16 | ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． | 認知機能を向上させるための植物抽出物 |
| CA2961378A1 (en) * | 2014-09-15 | 2016-03-24 | Kemin Industries, Inc. | Plant extracts for improving cognitive function |
| WO2016057818A1 (en) * | 2014-10-08 | 2016-04-14 | Abbott Laboratories | Nutritional compositions comprising an oxidizable component and water-soluble plant extract |
| ES2951079T3 (es) * | 2016-11-11 | 2023-10-17 | Kemin Ind Inc | Uso de un extracto de menta verde para mejorar la tasa de neurogénesis |
| CN106727915B (zh) * | 2017-01-18 | 2020-03-31 | 云南德彩堂生物医药科技有限公司 | 一种稳定高效提高记忆的组合物及其制备方法和应用 |
| BR112020008727A2 (pt) * | 2017-10-30 | 2020-10-20 | Neuropore Therapies, Inc. | fenil sulfonil fenil triazol tionas substituídas e usos destas |
| CN109602759B (zh) * | 2019-01-17 | 2020-10-09 | 广西医科大学 | 罗汉松实多糖的用途 |
| KR102421772B1 (ko) * | 2019-05-21 | 2022-07-18 | 건국대학교 글로컬산학협력단 | 클로로필 및 로즈마린산을 포함하는 미세먼지에 의해 유발된 신경염증 또는 신경 퇴행성 질환의 예방 또는 치료용 조성물 |
| CN110463846A (zh) * | 2019-07-30 | 2019-11-19 | 河南科技学院 | 留兰香提取物在制备抗宠物衰老药物或宠物食品中的应用 |
| JP7330630B2 (ja) * | 2019-11-20 | 2023-08-22 | 株式会社ニップン | ロスマリン酸及びカルノシン酸を有効成分とする神経突起伸長誘導作用を有する組成物 |
| JP2022104122A (ja) * | 2020-12-28 | 2022-07-08 | 株式会社ニップン | オキシトシン関連シグナル活性化剤 |
| EP4608384A1 (en) * | 2022-10-27 | 2025-09-03 | Kemin Industries, Inc. | Use of a spearmint extract for retina neurotrophism |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1219509C (zh) * | 1998-05-16 | 2005-09-21 | 财团法人牧岩生命工学研究所 | 迷迭香酸及其衍生物用于制备免疫抑制剂药物的用途 |
| JP4629822B2 (ja) * | 1999-12-02 | 2011-02-09 | 長瀬産業株式会社 | 神経成長因子合成促進剤 |
| JP2006199666A (ja) * | 2005-01-24 | 2006-08-03 | Nagase & Co Ltd | 健忘症の予防・治療剤 |
| JP2009512711A (ja) * | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP1930019A1 (en) * | 2006-11-24 | 2008-06-11 | DSMIP Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
| EP1925213A1 (en) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Dietary and pharmaceutical compositions comprising a sage extract comprising a mixture of tricyclic diterpenes and their derivatives and their uses |
| WO2008090474A2 (en) * | 2007-01-24 | 2008-07-31 | University Of Guelph | Production of rosmarinic acid from spearmint and uses thereof |
| US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
| EP2060192B9 (en) * | 2007-10-17 | 2016-05-04 | Rudolf Wild GmbH & Co. KG | Composition comprising lemon balm extracts |
| US9950019B2 (en) * | 2009-06-12 | 2018-04-24 | Generex Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of brain diseases and conditions |
| CN101773488A (zh) * | 2010-02-10 | 2010-07-14 | 青岛大学 | 一种基于迷迭香酸的药物及其在治疗帕金森病中的应用 |
| JP2011256118A (ja) * | 2010-06-07 | 2011-12-22 | Kao Corp | Ｉｌ−８及びｇｍ−ｃｓｆ発現抑制剤 |
-
2013
- 2013-08-08 US US13/962,609 patent/US20140044813A1/en not_active Abandoned
- 2013-08-09 WO PCT/US2013/054274 patent/WO2014026081A1/en not_active Ceased
- 2013-08-09 CN CN202010406999.5A patent/CN111358832A/zh active Pending
- 2013-08-09 CA CA2880708A patent/CA2880708C/en active Active
- 2013-08-09 PL PL13828399T patent/PL2882443T3/pl unknown
- 2013-08-09 AU AU2013299491A patent/AU2013299491B2/en active Active
- 2013-08-09 CN CN201380051858.4A patent/CN104684562A/zh active Pending
- 2013-08-09 EP EP13828399.9A patent/EP2882443B1/en active Active
- 2013-08-09 BR BR112015002739A patent/BR112015002739A2/pt not_active Application Discontinuation
- 2013-08-09 JP JP2015526726A patent/JP2015524484A/ja active Pending
- 2013-08-09 ES ES13828399T patent/ES2715005T3/es active Active
- 2013-08-09 KR KR1020157006128A patent/KR101947352B1/ko active Active
-
2021
- 2021-01-08 JP JP2021001953A patent/JP2021066735A/ja active Pending
-
2022
- 2022-12-09 JP JP2022196766A patent/JP2023027232A/ja active Pending
-
2024
- 2024-09-17 US US18/887,782 patent/US20250009703A1/en active Pending
- 2024-11-29 JP JP2024208100A patent/JP2025029029A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524484A5 (enExample) | ||
| Ghasemi et al. | Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder | |
| Ruan et al. | Neurogenesis in neurological and psychiatric diseases and brain injury: from bench to bedside | |
| Rief et al. | Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| WO2016070151A8 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| UY31748A (es) | Nuevos compuestos para el tratamiento de trastornos del snc (sistema nervioso central) | |
| Kandratavicius et al. | Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| MX2019002827A (es) | Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia. | |
| JP2016530291A5 (enExample) | ||
| Alamy et al. | Escitalopram in specific phobia: results of a placebo-controlled pilot trial | |
| JP2025530256A (ja) | ストレス関連障害の治療のためのｍｄｍａの使用 | |
| Gosek¹ et al. | Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy | |
| Roberto et al. | Adolescent catatonia successfully treated with Lorazepam and aripiprazole | |
| Holguín-Lew et al. | “When I Want to Cry I Can’t”: Inability to Cry Following SSRI Treatment | |
| WO2018192428A1 (zh) | 完全羧化骨钙素在制备快速抗抑郁药中的应用 | |
| Zimmerman et al. | Lack of Generalizability of PTSD Treatment Trials: The Recent Brexpiprazole-Sertraline Trials as an Example | |
| Gimbel | Evidence Based Practice Day | |
| Kim et al. | Convergence study on the change of cognitive function through the intentional finger movement | |
| Pereiro Gomez | Methylphenidate abuse | |
| Giacomin | Does community care works? Evaluate the effectiveness of mental health services | |
| Maruta et al. | SCHIZOPHRENIA WITH COMORBID OTHER MENTAL AND BEHAVIORAL DISORDERS (CLINICAL-PSYCHOPATHOLOGICAL AND PATHOPSYCHOLOGICAL CHARACTERISTICS, DIAGNOSTIC CRITERIA) | |
| Moreno et al. | Disruptive behaviour's treatment with paliperidone in autistic disorder: Review and case report | |
| Tester et al. | B vitamins enhance antidepressant response in adults |